Paradigm Biocapital Advisors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001855655

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 29 positions · Total reported value $5.03B · Top-10 concentration 78.6% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.3% · 7 new · 6 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Paradigm Biocapital Advisors LP disclosed 29 equity positions with a combined reported value of $5.03B. The filing implies a focused portfolio: its ten largest positions account for 78.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were RVMD ($1.28B), GMAB ($504.32M), EWTX ($437.61M). By sector, the heaviest allocations are Health Care 99.7%, Other 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+18.5pp) and away from Industrials (-0.8pp), Other (-17.7pp).

Versus the prior quarter, Paradigm Biocapital Advisors LP opened 7 new positions, trimmed 6 and fully exited 6, a turnover rate of 54.3% of positions. The portfolio's overlap with the prior quarter was 63% of names.

The largest new positions opened in Q3 2026 were BBIO ($154.49M), GPCR ($40.63M), MANE ($37.59M).

Of the 6 positions fully exited versus the prior quarter, the largest were NUVL ($731.67M), APGE ($209.23M), ALNY ($144.49M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • BBIO BRIDGEBIO PHARMA INC · $154.49M
  • GPCR STRUCTURE THERAPEUTICS INC · $40.63M
  • MANE VERADERMICS INC · $37.59M
  • ORIC ORIC PHARMACEUTICALS INC · $20.28M
  • ANIX KORSANA BIOSCIENCES INC · $19.65M
  • COAG HEMAB THERAPEUTICS HLDGS INC · $19.41M
  • TLGYF TCGX ACQUISITION CORP · $3.75M

Fully Exited (vs previous quarter)

  • NUVL NUVALENT INC · prev qtr: $731.67M
  • APGE APOGEE THERAPEUTICS INC · prev qtr: $209.23M
  • ALNY ALNYLAM PHARMACEUTICALS INC · prev qtr: $144.49M
  • EYPT EYEPOINT INC · prev qtr: $41.33M
  • MPLT MAPLIGHT THERAPEUTICS INC · prev qtr: $24.58M
  • LXEO LEXEO THERAPEUTICS INC · prev qtr: $19.44M

Insider Transactions (Form 4)

Latest Paradigm Biocapital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Paradigm Biocapital Advisors LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 28 positions worth $5.34B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-120338 (status: Approved), registered 2021-02-23
  • Regulatory AUM (Form ADV): $4.47B as of 2026-08-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 28 positions · $5.34B reported value (Q2 2026)
  • Top 10 holdings = 75.2% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 22.3%
  • Average position size: $190.73M

Sector Tilt

  • Health Care 81.2%
  • Industrials 0.8%
  • (classified holdings cover 82% of value)

Quarterly Activity

  • Q2 2026: 7 new, 12 added, 7 reduced, 14 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to high-growth biotech/healthcare names (e.g., INSM, VRDN, MBX) while trimming some established positions (RVMD, BLTE, TARS), suggesting a bullish stance on innovative therapeutics but selective profit-taking. 2. Key moves: - Added: GMAB (+3.28% wt), EWTX (+0.93% wt), SYRE (+1.51% wt), INSM (+3.47% wt), VRDN (+2.20% wt), MBX (+1.81% wt), ORKA (+0.31% wt). - Reduced: RVMD (-2.92% wt), BLTE (-0.30% wt), TARS (-0.33% wt). 3. Portfolio structure: Highly active, concentrated in Health Care (100% top-10), with aggressive growth bias (e.g., INSM +103% shares) and moderate risk appetite (top-10 holds 88.63% of $5B). 4. Per-holding one-liner: - RVMD: Revolution Medicines (oncology) - GMAB: Genmab A/S (antibody therapeutics) - EWTX: Edgewise Therapeutics (fibrosis) - SYRE: Spyre Therapeutics (inflammation) - INSM: Insmed Inc (antibiotics) - VRDN: Viridian Therapeutics (thyroid disease) - MBX: MBX Biosciences (unverified) - ORKA: Oruka Therapeutics (unverified) - BLTE: Belite Bio (eye diseases) - TARS: Tarsus Pharmaceuticals (ophthalmology) 5. Style summary: Aggressive biotech fund doubling down on high-growth clinical-stage names while trimming select large caps.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:02

Sector Allocation

Health Care 99.7%
Other 0.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 6.22M $1.28B 25.39%
25.39%
Reduce
2 14.14M $504.32M 10.03%
10.03%
Add
3 10.78M $437.61M 8.70%
8.70%
Add
4 4.46M $396.85M 7.89%
7.89%
Add
5 2.70M $307.72M 6.12%
6.12%
Add
6 12.41M $227.08M 4.51%
4.51%
Add
7 3.77M $221.17M 4.40%
4.40%
Add
8 2.49M $207.68M 4.13%
4.13%
Add
9 1.14M $193.96M 3.86%
3.86%
Reduce
10 2.30M $180.91M 3.60%
3.60%
Reduce
11 6.96M $173.69M 3.45%
3.45%
Add
12 2.35M $154.49M 3.07%
3.07%
New
13 2.14M $121.93M 2.42%
2.42%
Add
14 8.00M $117.25M 2.33%
2.33%
Reduce
15 6.05M $85.05M 1.69%
1.69%
Add
16 3.51M $76.77M 1.53%
1.53%
Add
17 8.72M $75.35M 1.50%
1.50%
Add
18 1.30M $40.63M 0.81%
0.81%
New
19 4.95M $40.06M 0.80%
0.80%
Hold
20 310.06K $37.59M 0.75%
0.75%
New
21 1.55M $36.50M 0.73%
0.73%
Hold
22 1.51M $20.28M 0.40%
0.40%
New
23 613.91K $19.65M 0.39%
0.39%
New
24 7.58M $19.47M 0.39%
0.39%
Add
25 629.35K $19.41M 0.39%
0.39%
New
26 889.58K $16.97M 0.34%
0.34%
Reduce
27 900.00K $13.28M 0.26%
0.26%
Hold
28 300.00K $3.75M 0.07%
0.07%
New
29 808.18K $2.98M 0.06%
0.06%
Reduce

FAQ

What did Paradigm Biocapital Advisors LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Paradigm Biocapital Advisors LP reported 29 equity positions worth $5.03B in aggregate; its largest disclosed positions were RVMD ($1.28B), GMAB ($504.32M), EWTX ($437.61M).

How large is Paradigm Biocapital Advisors LP's portfolio?

Paradigm Biocapital Advisors LP reported $5.03B of long equity holdings across 29 positions as of 2026-Q3. Top-10 holdings account for 78.6% of reported value.

What is Paradigm Biocapital Advisors LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/paradigm-biocapital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →